Back to results
US 12,729,234 B2Granted
Tau binding compounds
AssigneeVoyager Therapeutics, Inc.
InventorsVinodhbabu Kurella, Li Liu, Dillon Kavanagh, Allan D. Capili, Jinzhao Hou, Todd Carter, Wencheng Liu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides anti-tau antibodies. Also provided are methods of using anti-tau antibodies for treatment and diagnosis of neurological indications.
Claims17
An antibody that binds to tau comprising a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1), an HC CDR2, and an HC CDR3;
- and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1), LC CDR2, and an LC CDR3, wherein:
- (i) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 82, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 97, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 115, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 127, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 141, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 159;
- (ii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 79, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 94, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 111, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 127, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 141, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 156;
- (iii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 80, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 95, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 112, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 129, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 143, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 157;
- (iv) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 81, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 94, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 114, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 127, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 141, and the LC CDR3 comprises the amino acid sequences of SEQ ID NO:
- 156;
- (v) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 88, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 105, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 123, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 137, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 151, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 168;
- (vi) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 82, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 101, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 119, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 132, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 149, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 164;
- (vii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 86, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 102, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 120, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 127, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 141, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 156;
- (viii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 77, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 92, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 109, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 127, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 141, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 154;
- (ix) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 78, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 93, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 110, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 128, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 142, and LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 155;
- (x) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 78, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 96, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 113, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 130, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 144, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 158;
- (xi) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 83, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 98, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 116, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 131, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 145, and the LC CDR3 comprises the amino acid sequences of SEQ ID NO:
- 160;
- (xii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 84, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 99, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 117, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 132, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 146, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 161;
- (xiii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 85, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 100, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 118, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 133, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 147, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 162;
- (xiv) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 85, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 100, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 118, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 134, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 148, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 163;
- (xv) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 87, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 103, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 121, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 132, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 149, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 165;
- (xvi) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 78, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 104, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 122, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 135, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 143, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 166;
- (xvii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 78, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 104, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 122, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 136, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 150, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 167;
- (xviii) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 89, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 106, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 124, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 138, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 152, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 169;
- (xix) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 90, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 107, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 125, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 139, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 151, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 170;
- or
- (xx) the HC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 91, the HC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 108, the HC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 126, the LC CDR1 comprises the amino acid sequence of SEQ ID NO:
- 140, the LC CDR2 comprises the amino acid sequence of SEQ ID NO:
- 153, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 171.
139 more elements
An antibody that binds to tau comprising a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO:
- 82, an HC CDR2 comprising the amino acid sequence of SEQ ID NO:
- 101, and an HC CDR3 comprising the amino acid sequence of SEQ ID NO:
- 119;
- and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO:
- 132, an LC CDR2 comprising the amino acid sequence of SEQ ID NO:
- 149, and an LC CDR3 comprises the amino acid sequence of SEQ ID NO:
- 164.
4 more elements
Dependencies are inferred from the claim text.